% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Maa:139503,
author = {Maaß, Anne and Landau, Susan and Baker, Suzanne L and
Horng, Andy and Lockhart, Samuel N and La Joie, Renaud and
Rabinovici, Gil D and Jagust, William J and Initiative,
Alzheimer's Disease Neuroimaging},
title = {{C}omparison of multiple tau-{PET} measures as biomarkers
in aging and {A}lzheimer's disease.},
journal = {NeuroImage},
volume = {157},
issn = {1053-8119},
address = {Orlando, Fla.},
publisher = {Academic Press},
reportid = {DZNE-2020-05825},
pages = {448-463},
year = {2017},
abstract = {The recent development of tau-specific positron emission
tomography (PET) tracers enables in vivo quantification of
regional tau pathology, one of the key lesions in
Alzheimer's disease (AD). Tau PET imaging may become a
useful biomarker for clinical diagnosis and tracking of
disease progression but there is no consensus yet on how tau
PET signal is best quantified. The goal of the current study
was to evaluate multiple whole-brain and region-specific
approaches to detect clinically relevant tau PET signal. Two
independent cohorts of cognitively normal adults and
amyloid-positive (Aβ+) patients with mild cognitive
impairment (MCI) or AD-dementia underwent [18F]AV-1451 PET.
Methods for tau tracer quantification included: (i) in vivo
Braak staging, (ii) regional uptake in Braak composite
regions, (iii) several whole-brain measures of tracer
uptake, (iv) regional uptake in AD-vulnerable voxels, and
(v) uptake in a priori defined regions. Receiver operating
curves characterized accuracy in distinguishing Aβ-
controls from AD/MCI patients and yielded tau positivity
cutoffs. Clinical relevance of tau PET measures was assessed
by regressions against cognition and MR imaging measures.
Key tracer uptake patterns were identified by a factor
analysis and voxel-wise contrasts. Braak staging, global and
region-specific tau measures yielded similar diagnostic
accuracies, which differed between cohorts. While all tau
measures were related to amyloid and global cognition,
memory and hippocampal/entorhinal volume/thickness were
associated with regional tracer retention in the medial
temporal lobe. Key regions of tau accumulation included
medial temporal and inferior/middle temporal regions,
retrosplenial cortex, and banks of the superior temporal
sulcus. Our data indicate that whole-brain tau PET measures
might be adequate biomarkers to detect AD-related tau
pathology. However, regional measures covering AD-vulnerable
regions may increase sensitivity to early tau PET signal,
atrophy and memory decline.},
keywords = {Adult / Age of Onset / Aged / Aged, 80 and over / Aging:
metabolism / Alzheimer Disease: diagnostic imaging /
Alzheimer Disease: metabolism / Alzheimer Disease: pathology
/ Alzheimer Disease: physiopathology / Amyloid
beta-Peptides: metabolism / Carbolines / Cognitive
Dysfunction: diagnostic imaging / Cognitive Dysfunction:
metabolism / Cognitive Dysfunction: pathology / Cognitive
Dysfunction: physiopathology / Cohort Studies / Female /
Humans / Male / Middle Aged / Neocortex: diagnostic imaging
/ Neocortex: metabolism / Positron-Emission Tomography:
methods / Severity of Illness Index / Young Adult / tau
Proteins: metabolism / Amyloid beta-Peptides (NLM Chemicals)
/ Carbolines (NLM Chemicals) / tau Proteins (NLM Chemicals)
/ 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (NLM
Chemicals)},
cin = {AG Düzel},
ddc = {610},
cid = {I:(DE-2719)5000006},
pnm = {344 - Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28587897},
pmc = {pmc:PMC5814575},
doi = {10.1016/j.neuroimage.2017.05.058},
url = {https://pub.dzne.de/record/139503},
}